Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Home - The Pharma Times | Pharma & Health Care News Portal
Thursday, April 25, 2024

Conjunctivitis at its peak by NIIMS

New Delhi, August 17, 2023: Conjunctivitis or pink eyes or red eyes is spreading at a fast rate. It is highly infectious and might...

Lupin receives FDA approval for its Oral Contraceptive Kurvelo® Tablets; The...

Mumbai, Baltimore, October 18, 2012:   – Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its oral contraceptive Kurvelo® Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP) 0.15 mg/0.03 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Teva Branded Pharmaceuticals (Teva) Nordette® Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP), 0.15 mg/0.03 mg.

Lupin's Kurvelo® Tablets are the AB-rated generic equivalent of Teva's Nordette® Tablets. Lupin's Kurvelo® tablets is a Levonorgestrel and Ethinyl estradiol combined oral contraceptive indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Lupin is marketing its Kurvelo® tablets in 21 light orange colored active tablets containing 0.15 mg Levonorgestrel and 0.03 mg Ethinyl estradiol and seven pink inert tablets (without hormones). This dosage regimen is identical to that of Nordette®.

Biotechnology

Surge in Avascular Necrosis of the Femoral Head in India Post-COVID: A Closer Look...

New Delhi, August 21, 2023: The COVID-19 pandemic has cast an unprecedented shadow over the world, disrupting lives and healthcare systems in ways we never...

IT & Software Support

Wipro GE Healthcare keen to make diagnostics affordable to all

Wipro GE Healthcare is keen to invest in technologies that are affordable to all.

Terri Bresenhem, President and Chief Executive, GE Healthcare, told reporters here on Wednesday that the company has not only been expanding its presence in India for over two decades now, but investing at least 30 per cent more in recent years. “The investment is both in terms of manpower and strengthening our research and development facility,” she said.

INDIA MANUFACTURE

“We are striving to make healthcare affordable to all. While most medical equipment companies that have established their presence here import close to 80 per cent of their equipment, our import component is less. At GE Healthcare, we design and manufacture 30 per cent of the equipment in India. We have a strong research team, high quality thinkers and innovators here,” she added.

Appointments

Anno Borkowsky appointed to the LANXESS Board of Management

Taking charge of Specialty Additives segment Reorganization of the Additives business units  Cologne, June 11, 2019: The Supervisory Board of LANXESS AG has appointed...

Awards

ISF College of Pharmacy Organized Convocation-2021

* Degrees awarded to 250 students in the convocation, Moga New Delhi, January 8, 2022: Convocation-2021 of  ISF College of Pharmacy inaugurated Chief guest Dr....

Financial Results

Approvals

Clinical Trails

Dalmia Healthcare Starts Clinical Trial with its Ayurvedic Composition to Treat COVID-19

New Delhi, June 04, 2020: Dalmia Healthcare, the healthcare division of Dalmia Group led by renowned industrialist Sanjay Dalmia, starts clinical trial to evaluate the efficacy...

Bulk Drug

Health Care

Alternative Medicine

Eye Care

Digital Eye Strain Affects Children Now More than Ever

By  Dr. Anand Balasubramaniam, Senior Consultant Cornea, Sankara Eye hospital Bangalore The current lock down due to COVID-19 pandemic has led to the biggest self-isolation...

Product News

Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting

New Delhi, May 17, 2020: Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase...

Media Partners

Spotlight

Investments

Packaging

Latest News

Fostering collaborations with stakeholders is key: Amit Chopra

New Delhi, September  27, 2023:  “On World Environmental Health Day, we reaffirm our unwavering commitment to being a good steward of our planet and...

Emerging Biomarkers for Lung Cancer Diagnosis and Prognosis

Dr. Kapil Uttamrao Raut, MBBS, MD Medicine, DM Medical oncology, ECMO (UK) , Medical Oncology, HCG NCHRI Cancer Centre, Nagpur Lung cancer, a devastating disease...

CORE Diagnostics embarks on its national expansion plans, launches two new labs in Delhi...

State-of-the-art Laboratory in Richmond Circle, Bengaluru and in Green Park, Delhi Both the facilities are spread over 5000 square feet of lab space, broadening range of...

6th Annual Pharma Project & Portfolio Management 2023

26th, 27th & 28th of April, 2023 ABOUT THE EVENT To the most demanding and accountability-driven teams of the Pharma Industry, an event awaits you! The success...

Dental Care

The Global Dental and Diagnostics Surgical Equipment Market on The Rise

New Delhi, February 16, 2022: As of recent research, it has been predicted that the global dental and diagnostics surgical instrument industry is all...

Hospital Management

Drug Discovery & Development

Suppliers

Technology

Companies

Hyderabad to have Telugu States first Plasma Bank The Rotary...

New Delhi, August 25, 2020: The only hope to Corona until Vaccine introduced is Plasma Therapy. Making that easy is Plasma Hyderabad to have Telugu...

BD inaugurates Centre of Excellence in Flow Cytometry at IISER, Pune

The new centre is aimed at increasing research capabilities in India Pune, June 13, 2019: BD Life Sciences-Biosciences, a segment of BD (Becton, Dickinson and...

Marketing

Our Partners

Machinery & Equipments